The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
CV results yesterday were from Spain and we know we won't hear of any orders until CE mark by early May. We also know that validation is taking place in the UK (as per the Feb RNS). Of course, CE mark is no longer required in the UK. So I believe a big sovereign test announcement of UK CV results and government order is imminent. Very exciting times!
I call BS, Wolves. You were deramping for ages in a foolish attempt to try and lower the share price before buying in late last year / early 2021.
GAD have been awarded £1,15 billion to manufacture lateral flow tests for Covid-19. Not long now till we find out the magic ingredient within these LFTs!!! (https://bidstats.uk/tenders/2021/W11/747045154 )
Yeah, the share can be impossible to buy/sell at times. I certainly couldn't sell after the Pfizer vaccine announcement. Was trying to sell as it dropped to 1.50 but I couldn't put it through and the share price continued to drop to close to a pound if memory serves.
I'm a long term holder and don't trade so have no dog in the fight, but I don't think we'll get an intraday RNS announcing CV results / CE Mark as some have suggested. This will only happen if there is a public leak. The only share-price affecting intraday RNS we have had was the one on 30th Sep at 10:35 announcing that the BAMS assay to detect the SARS-CoV-2 virus had been launched and was on sale as a research kit by Adeptrix. The reason this was not a 7am RNS was because Avacta were unaware that the kit was being sold and actually it was a sleuth on this BB who spotted it on the Adeptrix website and informed us all. Avacta picked-up on the chatter that morning and hence the RNS at 10:35
We've been informed that CV results and CE mark will be in around the end of Q1 and some on this board interpreted 'around' to include April. I disagree and am sure the results will be in before end of March. In the latest interview Sir Al mentioned that the LFT would have taken a year to develop but he then corrected himself to under a year. The collaboration with Cytiva was announced on 8th April. Of course, CV results & CE mark on 7th April would be under a year but again Sir Al seemed confident it would be under a year so the CV results and CE mark won't be going to the wire of 7th April. Exciting times!
no wonder you are called MrBlue, cheer-up mate!
Damn autocorrect, i meant autocorrect not autocrat!
Damn autocrat, I meant changing lanes to the lft
Thanks gkb47. Changing lanes to the left. Alastair acknowledged that getting covid-19 samples was more difficult due to lockdown and slowdown of the spread. So he is getting feedback on the number of tests being performed for CV. Does the feedback he receive include the results to date? He seems supremely confident so I’m interested to know, can anyone advise, thanks.
oops, my bad. Thanks
Great interview today with loads of information and detail for investors. It's good to know Avacta can produce the Affimers for diagnostics but what I found interesting is that Affimers for therapeutics have to be manufactured under more stringent conditions i.e. follow Good Manufacturing Practice (GMP). Alastair stated that the licence partners are responsible for Affimer GMP because Avacta do not have this standard of manufacturing.
What I am wondering is how will Avacta produce the affimers for the AVA6000 pro-doxorubicin trial if they do not meet the GMP requirement for affimer production? Can anybody enlighten me please?
That is an exceedingly good post Mr Kipling
It wasn't a good post from Mr Kippling, it was exceedingly good!
Monkshood, you should not pose as the board's resident scientist if you don't know what you're talking about. People like a chap called Egbert on twitter seem to respect your opinion and follow your lead. It's not fair to misinform fellow holders. Not that it was in doubt from my point of view, but today Avacta confirmed the sampling method analysed for the clinical data was anterior nasal.
I quote "...the Company has analysed the first clinical data for its SARS-CoV-2 rapid antigen test from ongoing studies in Europe and the UK . These data show excellent performance of the test in identifying patients with an infectious viral load, with 96.7% sensitivity and 100% specificity using anterior nasal swab samples from 30 COVID-19 positive patients and 26 negative individuals."
Does anybody know where I can find the AVA6000 Clinical Trial Protocol? Thanks in advance.
I noticed one or two posters on here and twitter stated that the AffiDX™ clinical testing would have used the nasopharyngeal (brain-tickler) method and the S & S results won't be as good when full clinical testing is performed using the Anterior Nasal (non-invasive, tip of the nostril test) method. Let's debunk this myth, the AffiDX™ testing announced yesterday would have been performed as they will be in 'real-life' i.e. Anterior Nasal method.
I notice a chap called Ophidian is receiving plaudits both here and on twitter for being the first to link Avacta with Mologic for the Covid-19 LFT. I’m a firm believer in credit where credit is due and would like to make it clear, and I’m blushing as I type this, that goldstandard (AKA Columbo) first made this connection on 22nd January in this thread…just one more thing…
Need one more contract win and we break the £1
Zero Abingdon tweets from 24 Nov - 18 Jan (save for one tweet on 15 Dec to announce AIM admission). They were prolific tweeters from 1st-23 Nov with 59 tweets. They tweeted 13 times from 19-31 Jan and are prolific again in Feb with 14 tweets to 3rd Feb.
Zero BBI tweets from 18 Dec - 28 Jan (save for a season's greetings tweet on 23 Dec). Then 2 tweets end of Jan and 3 so far in Feb.
Zero Omega tweets from 30 Dec - 11 Jan followed by 17 tweets in rest of Jan and a prolific 14 tweets in 3 days of Feb.
And your point is? I hear you cry. Even when you take into account the holiday period, it is clear to see these companies were told to hold off the tweeting. It appears that the shackles are off now. You also will notice that the tweets being released are about antibody tests. It's as if these companies were instructed not to tweet about antigen LFTs. I wonder why that might be?!